A Prospective Database of Infants With Cholestasis
| Status: | Recruiting | 
|---|---|
| Conditions: | Gastrointestinal | 
| Therapuetic Areas: | Gastroenterology | 
| Healthy: | No | 
| Age Range: | Any | 
| Updated: | 2/27/2019 | 
| Start Date: | May 2004 | 
| End Date: | May 2019 | 
| Contact: | Joanne Lord, LPN, BA,CCRC | 
| Email: | joanne.lord@arborresearch.org | 
| Phone: | 734 369-9965 | 
Childhood Liver Disease Research Network (ChiLDReN): A Prospective Database of Infants With Cholestasis
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions
are the most common causes of jaundice and hyperbilirubinemia that continue beyond the
newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN)
is to establish a database of clinical information and plasma, serum, and tissue samples from
cholestatic children to facilitate research and to perform clinical, epidemiological and
therapeutic trials in these important pediatric liver diseases.
			are the most common causes of jaundice and hyperbilirubinemia that continue beyond the
newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN)
is to establish a database of clinical information and plasma, serum, and tissue samples from
cholestatic children to facilitate research and to perform clinical, epidemiological and
therapeutic trials in these important pediatric liver diseases.
This is a multi-center project to establish a prospective database of clinical information
and a repository of blood, and tissue samples from children with diagnoses of neonatal liver
diseases, such as biliary atresia (BA), idiopathic neonatal hepatitis (INH), and specific
neonatal presentations of genetic cholestatic disorders in order to perform research in these
important liver problems. Children will be screened and enrolled at presentation at the
participating pediatric liver sites. Participants diagnosed with BA will be followed
intensively for the first year, at 18 months of age, and then annually up to 20 years of age,
or liver transplantation. Other participants diagnosed with cholestasis will be followed on
the same schedule; if there is complete (clinical and biochemical) resolution of their
underlying liver disease off all therapy, there will be one follow up visit within one year
(preferably scheduled at the time of the next planned follow up visit or at 12 months of age,
whichever is later) for data collection and to obtain blood samples. The development of a
serum and tissue bank of specimens from children with various neonatal cholestatic disorders
will be an invaluable tool for current and future investigations into the etiology and
pathogenesis of hepatobiliary injury in the infant.
Detailed clinical data, laboratory investigations, liver and biliary specimens, and long-term
follow-up of outcomes are part of the normal standard of care with respect to the diagnosis
and treatment of the subjects with liver problems. This research involves the collection of
diagnostic, clinical and outcome data concerning the subject, which is kept without
identification (coded) in a national research database of infants with liver disease. Samples
of blood will be obtained for later research analysis, whenever possible, at the time of
clinically indicated blood draws or when there is IV access for a clinical procedure. When
liver biopsy specimens are obtained for diagnostic purposes, any liver biopsy specimen in
excess of that needed for diagnostic use will be sent to the tissue repository. When a
portoenterostomy or liver transplant occurs, sections of the liver and, biliary remnant
removed in the course of surgery and in excess of that needed for diagnostic use, will be
sent for the repository. These specimens will be used in investigations into the mechanisms
and causes of the liver damage that occur in the participant's condition. . All data from
this study will be kept in a secure research database at the DCC and transferred to the NIDDK
data repository after the study ends.
and a repository of blood, and tissue samples from children with diagnoses of neonatal liver
diseases, such as biliary atresia (BA), idiopathic neonatal hepatitis (INH), and specific
neonatal presentations of genetic cholestatic disorders in order to perform research in these
important liver problems. Children will be screened and enrolled at presentation at the
participating pediatric liver sites. Participants diagnosed with BA will be followed
intensively for the first year, at 18 months of age, and then annually up to 20 years of age,
or liver transplantation. Other participants diagnosed with cholestasis will be followed on
the same schedule; if there is complete (clinical and biochemical) resolution of their
underlying liver disease off all therapy, there will be one follow up visit within one year
(preferably scheduled at the time of the next planned follow up visit or at 12 months of age,
whichever is later) for data collection and to obtain blood samples. The development of a
serum and tissue bank of specimens from children with various neonatal cholestatic disorders
will be an invaluable tool for current and future investigations into the etiology and
pathogenesis of hepatobiliary injury in the infant.
Detailed clinical data, laboratory investigations, liver and biliary specimens, and long-term
follow-up of outcomes are part of the normal standard of care with respect to the diagnosis
and treatment of the subjects with liver problems. This research involves the collection of
diagnostic, clinical and outcome data concerning the subject, which is kept without
identification (coded) in a national research database of infants with liver disease. Samples
of blood will be obtained for later research analysis, whenever possible, at the time of
clinically indicated blood draws or when there is IV access for a clinical procedure. When
liver biopsy specimens are obtained for diagnostic purposes, any liver biopsy specimen in
excess of that needed for diagnostic use will be sent to the tissue repository. When a
portoenterostomy or liver transplant occurs, sections of the liver and, biliary remnant
removed in the course of surgery and in excess of that needed for diagnostic use, will be
sent for the repository. These specimens will be used in investigations into the mechanisms
and causes of the liver damage that occur in the participant's condition. . All data from
this study will be kept in a secure research database at the DCC and transferred to the NIDDK
data repository after the study ends.
INCLUSION CRITERIA
- Infant's age less than or equal to 180 days at initial presentation at the ChiLDREN
clinical site.
- Diagnosis of cholestasis defined by serum direct or conjugated bilirubin greater than
20% of total and greater than or equal to 2 mg/dl.
- The subject's parent(s)/guardian(s) willing to provide informed written consent.
EXCLUSION CRITERIA
- Acute liver failure.
- Previous hepatobiliary surgery with dissection or excision of biliary tissue.
- Diagnoses of bacterial or fungal sepsis (except where associated with metabolic liver
disease)
- Diagnoses of hypoxia, shock or ischemic hepatopathy within the past two weeks (If the
cholestasis persists beyond two weeks of the initiating event, the infant can be
enrolled).
- Diagnosis of any malignancy.
- Presence of any primary hemolytic disease (except when diagnosed with biliary atresia
or another cholestatic disease being studied by ChiLDREN).
- Diagnosis of any drug or TPN-associated cholestasis (except when diagnosed with
biliary atresia or another cholestatic disease being studied by ChiLDREN).
- Diagnosis with ECMO-associated cholestasis.
- Birth weight less than 1500g (except when diagnosed with biliary atresia).
We found this trial at
    16
    sites
	
								Atlanta, Georgia 30322			
	
			
					Principal Investigator: Saul Karpen, MD, PhD
			
						
										Phone: 404-785-3690
					Click here to add this to my saved trials
	
									3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
	
			Cincinnati, Ohio 45229
 1-513-636-4200  
							
					Principal Investigator: Jorge Bezerra, MD
			
						
										Phone: 513-636-7818
					
		Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...  
  
  Click here to add this to my saved trials
	
									1200 Moursund Street
Houston, Texas 77030
	
			Houston, Texas 77030
(713) 798-4951 
							
					Principal Investigator: Paula Hertel, MD
			
						
										Phone: 832-822-1053
					
		Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...  
  
  Click here to add this to my saved trials
	
									4650 Sunset Blvd
Los Angeles, California 90027
	
			Los Angeles, California 90027
 (323) 660-2450 
							
					Principal Investigator: Kasper Wang, MD
			
						
										Phone: 323-361-4566
					
		Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...  
  
  Click here to add this to my saved trials
	
		Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...  
  
  Click here to add this to my saved trials
	
									South 34th Street
Philadelphia, Pennsylvania 19104
	
			Philadelphia, Pennsylvania 19104
 215-590-1000 
							
					Principal Investigator: Kathleen Loomes, MD
			
						
										Phone: 215-590-2525
					
		Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...  
  
  Click here to add this to my saved trials
	
									201 Presidents Circle
Salt Lake City, Utah 84108
	
			Salt Lake City, Utah 84108
801) 581-7200 
							
					Principal Investigator: Stephen Guthery, MD
			
						
										Phone: 801-585-9495
					
		University of Utah Research is a major component in the life of the U benefiting...  
  
  Click here to add this to my saved trials
	
									13123 E 16th Ave
Aurora, Colorado 80045
	
			Aurora, Colorado 80045
(720) 777-1234
							
					Principal Investigator: Ronald Sokol, MD
			
						
										Phone: 720-777-4690
					
		Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...  
  
  Click here to add this to my saved trials
	Click here to add this to my saved trials
	
									225 E Chicago Ave
Chicago, Illinois 60611
	
			Chicago, Illinois 60611
(312) 227-4000
							
					Principal Investigator: Estella Alonso, MD
			
						
										Phone: 312-227-3523
					
		Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children  
  
  Click here to add this to my saved trials
	
									705 Riley Hospital Dr
Indianapolis, Indiana 46202
	
			Indianapolis, Indiana 46202
(317) 944-5000
							
					Principal Investigator: Jean Molleston, MD
			
						
										Phone: 317-944-1421
					
		Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...  
  
  Click here to add this to my saved trials
	
								Pittsburgh, Pennsylvania 15224			
	
			
					Principal Investigator: Robert Squires, MD
			
						
										Phone: 412-692-7703
					Click here to add this to my saved trials
	
									660 S Euclid Ave
Saint Louis, Missouri 63110
	
			Saint Louis, Missouri 63110
(314) 362-5000 
							
					
		Washington University School of Medicine Washington University Physicians is the clinical practice of the School...  
  
  Click here to add this to my saved trials
	Click here to add this to my saved trials
	
									4800 Sand Point Way NE
Seattle, Washington 98105
	
			Seattle, Washington 98105
(206) 987-2000
							
					Principal Investigator: Karen Murray, MD
			
						
										Phone: 206-987-1037
					
		Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...  
  
  Click here to add this to my saved trials
	Click here to add this to my saved trials